Drug Approval | February 21, 2025
Lupin receives EIR from USFDA for its Somerset manufacturing facility
the inspection conducted from January 27 to January 31, 2025
the inspection conducted from January 27 to January 31, 2025
The Alathur facility specializes in the production of Cephalosporin antibiotics
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
This rating reflects Lupin's leadership in environmental transparency and performance
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
